Australian-New Zealand Clinical Trial: Pomaglumetad methionil in first-episode psychosis and clinical high-risk for psychosis.

Australia, Nov. 2 -- The Australian New Zealand Clinical Trials Registry (ANZCTR) received information related to the study titled ‘Pomaglumetad methionil in first-episode psychosis and clinical high-risk for psychosis.’. The following are the other relevant details related to the trial:

Trial ID: 388924

Submit Date: 9/21/26 12:42

Study Type: Interventional

Intervention: Intervention: Pomaglumetad methionil in first-episode psychosis and clinical high-risk for psychosis Dose: 40mg pomaglumetad twice daily (BID) Duration of treatment at full study dose (80mg): 12 weeks Mode of delivery: Oral administration Up-titration and down-titration at half study dose (40mg): 2 weeks each at 40mg pomaglumetad once daily (QD). Total duration of treat...